
    
      The study will be an open, uncontrolled, single-center, phase I study to assess the safety
      and tolerability of local intra-tumoral injection 2.0ml (660mg), 4.0ml (1220mg), 6.0ml
      (1880mg) and 8.0ml (2440mg) PTS in female breast cancer patients.
    
  